MK-2894 sodium salt is primarily utilized in the field of pharmaceutical research and development. It is a selective EP4 receptor antagonist explored for its potential therapeutic applications, particularly in the treatment of inflammatory diseases such as rheumatoid arthritis and associated pain conditions. Researchers investigate its efficacy in modulating prostaglandin E2 (PGE2)-mediated biological pathways to reduce inflammation and manage symptoms of chronic inflammatory disorders. Additionally, it is studied for its role in pain management and potential anti-cancer properties, as it may inhibit cancer cell growth through EP4 pathway blockade. The compound is also of interest in preclinical studies to understand its pharmacokinetics, safety profile, and potential interactions with other drugs, paving the way for future clinical trials and therapeutic use.